Catégorie : Cannabidiol

Cannabinoid Delivery Systems for Pain and Inflammation Treatment, Natascia Bruni et al., 2018

Cannabinoid Delivery Systems for Pain and Inflammation Treatment Natascia Bruni, Carlo Della Pepa, Simonetta Oliaro-Bosso, Enrica Pessione, Daniela Gastaldi and Franco Dosio Molecules, 2018, 23, 2478 doi:10.3390/molecules23102478        www.mdpi.com/journal/molecules Abstract : There is a growing body of evidence to suggest that cannabinoids are beneficial for a range of clinical conditions, including pain, inflammation, epilepsy, sleep disorders, the symptoms of multiple sclerosis, anorexia, schizophrenia and other conditions. The transformation of cannabinoids from herbal preparations into highly regulated prescription drugs is therefore progressing rapidly. The development of such drugs requires well-controlled clinical trials to be carried out in order to objectively establish therapeutic efficacy, dose ranges and [...]

Lire la suite

CANNABIS ET CANNABIDIOL : ÉLÉMENTS DE COMPRÉHENSION, DR SARAH LEJCZAK , 2019

CANNABIS ET CANNABIDIOL : Éléments de Compréhension Dr Sarah Lejczak La Lettre du RESPADD, 35, avril 2019   Depuis 5000 ans, le cannabis ruderalids, sativa ou indica est utilisé dans la pharmacopée humaine de manière informelle pour ses différentes propriétés antihémétiques, antiépileptiques, antispastiques, antalgiques, anxiolytiques, antihypertensives, etc. (1). Suite à son introduction dans l’arsenal pharmaceutique moderne au XIXème siècle et les dérives d’utilisation récréative au cours du XXème siècle, son utilisation a été interdite et reste très controversée de nos jours. Des extraits cannabinoïdes (2) (Delta-9-tetrahydrocannabinol (Δ-9-THC), cannabidiol (CBD) et cannabinol (CBN) majoritairement) de la plante ou fabriqués synthétiquement sont utilisés depuis 1985 en tant que médicaments. [...]

Lire la suite

Overcoming the Bell‐Shaped Dose‐Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol, Ruth Gallily et al.,

Overcoming the Bell‐Shaped Dose‐Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol Ruth Gallily, Zhannah Yekhtin, Lumír Ondřej Hanuš Pharmacology & Pharmacy, 2015, 6, 75-85 http://dx.doi.org/10.4236/pp.2015.62010 Abstract : Cannabidiol (CBD), a major constituent of Cannabis, has been shown to be a powerful anti inflammatory and anti‐anxiety drug, without exerting a psychotropic effect. However, when given either intraperitoneally or orally as a purified product, a bell‐shaped dose‐response was observed, which limits its clinical use. In the present study, we have studied in mice the anti‐inflammatory and anti nociceptive activities of standardized plant extracts derived from the Cannabis sativa L., clone 202, which is highly enriched [...]

Lire la suite

Modulation of Astrocyte Activity by Cannabidiol, a Nonpsychoactive Cannabinoid, Ewa Kozela et al., 2017

Modulation of Astrocyte Activity by Cannabidiol, a Nonpsychoactive Cannabinoid. Ewa Kozela, Ana Juknat, and Zvi Vogel International Journal of Molecular Sciences, 2017, 18, 1669, 20 pp. doi:10.3390/ijms18081669 PMID : 28788104   PMCID : PMC5578059 Abstract The astrocytes have gained in recent decades an enormous interest as a potential target for neurotherapies, due to their essential and pleiotropic roles in brain physiology and pathology. Their precise regulation is still far from understood, although several candidate molecules/systems arise as promising targets for astrocyte-mediated neuroregulation and/or neuroprotection. The cannabinoid system and its ligands have been shown to interact and affect activities of astrocytes. Cannabidiol (CBD) is the main [...]

Lire la suite

Cannabinoïd-Based Therapies and Brain Development: Potential Harmful Effect of Early Modulation of the Endocannabinoid System, Patricia Schonhofen et al., 2018,

Cannabinoïd-Based Therapies and Brain Development: Potential Harmful Effect of Early Modulation of the Endocannabinoid System Patricia Schonhofen, Ivi Juliana Bristot, Jose Alexandre Crippa et al. CNS Drugs,  2018, 32(Suppl 1), 1-16 DOI : 10.1007/s40263-018-0550-4   Abstract The endocannabinoid retrograde signaling pathway is widely expressed in the central nervous system, where it plays major roles in regulating synaptic plasticity (excitatory and inhibitory) through long-term potentiation and long-term depression. The endocannabinoid system (ECS) components—cannabinoid receptors, endocannabinoids and synthesis/degradation enzymes—are expressed and are functional from early developmental stages and throughout adolescent cortical development, regulating progenitor cell fate, neural differentiation, migration and survival. This may potentially confer increased vulnerability to [...]

Lire la suite

Cannabis, Cannabidiol, and Epilepsy. Clinical Considerations and Practical ApplicationsA new frontier brings new questions and old dilemmas, Adrian L. Turner and M. Scott Perry, 2018

Cannabis, Cannabidiol, and Epilepsy. Clinical Considerations and Practical Applications A new frontier brings new questions and old dilemmas. Adrian L. Turner and M. Scott Perry Practical Neurology, October 2018, 31-35 Background As early as 12,000 BCE, texts from central Asia reported human use of cannabis for nonmedical indications including ropes, fibers, and cloth. Ancient Chinese manuscripts from approximately 10,000 years later give the first documented use of cannabis for medical purposes 1. Other early reports from ancient Mesopotamia, Persia, and India describe cannabis use for indications such as spasticity, depression, anxiety, and epilepsy.1,2 Cannabis for medicinal purposes was not scientifically studied until the 19th century. In 1840, William [...]

Lire la suite

Neuroimaging Studies of Acute Effects of THC and CBD in Humans and Animals : a Systematic Review, Albert Batalla et al., 2014

Neuroimaging Studies of Acute Effects of THC and CBD in Humans and Animals : a Systematic Review A. Batalla, J.A. Crippa, G.F. Busatto, F.S. Guimarães, A.W. Zuardi, O. Valverde, Z. Atakan, P.K. McGuire, S. Bhattacharyya and R. Martín-Santos Current Pharmaceutical Design, 2014,  20, 2168-2185 DOI : 10.2174/13816128113199990432 Available from: https://www.researchgate.net/publication/247154314_Neuroimaging_Studies_of_Acute_Effects_of_THC_and_CBD_in_Humans_and_Animals_a_Systematic_Review [accessed May 19, 2019]. Abstract : Background : In recent years, growing concerns about the effects of cannabis use on mental health have renewed interest in cannabis research. In particular, there has been a marked increase in the number of neuroimaging studies of the effects of cannabinoids. We conducted a systematic review to assess the [...]

Lire la suite

Investigational Cannabinoids in Seizure Disorders, what have we learned thus far ?, Dejana Ružić Zečević et al., 2018

Investigational Cannabinoids in Seizure Disorders, what have we learned thus far ? Dejana Ružić Zečević, Ziyad Tantoush, Marko Folić, Goran Babić, Milan Radovanović and Slobodan M. Janković may 2018, 23 pages ABSTRACT Introduction : Anticonvulsant activity of cannabinoid attracted much attention in the last decade. Cannabinoids that are currently investigated with intention to become drugs for treatment of epilepsy are cannabidiol, cannabidivarin, Δ9-tetrahydrocannabivarin and Δ9-tetrahydrocannabinolic acid. Areas covered : Topic of this review are results of pre-clinical and clinical studies with investigational cannabinoids. Relevant literature was searched for in MEDLINE, SCOPUS, EBSCO, GOOGLE SCHOLAR and SCINDEX databases. Expert opinion : Pre-clinical studies confirmed anticonvulsant activity of [...]

Lire la suite

A Phase I, Randomized, Double‑Blind, Placebo‑Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects, Lesley Taylor et al., 2018

A Phase I, Randomized, Double‑Blind, Placebo‑Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects Lesley Taylor,·Barry Gidal,·Graham Blakey, Bola Tayo, Gilmour Morrison CNS Drugs, 2018 https://doi.org/10.1007/s40263-018-0578-5 Abstract Background : A formal single ascending and multiple dose pharmacokinetic (PK) trial of cannabidiol (CBD) oral solution was required to determine the safety and tolerability of CBD, the maximum tolerated dose, and to examine the effect of food on CBD PK parameters. Objective : This trial assessed the safety, tolerability and PK of CBD oral solution in healthy adult volunteers, as well as the effect [...]

Lire la suite

Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy : A Systematic Review, Jasmine Turna et al., 2019

Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy : A Systematic Review Jasmine Turna, Sabrina K. Syan, Benicio N. Frey, Brian Rush, Mary Jean Costello, Mark Weiss, and James MacKillop ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH, 2019, 1-14   Abstract : There is substantial interest in the therapeutic potential of cannabidiol (CBD), a nonpsychoactive cannabinoid found in plants of the genus Cannabis. The goal of the current systematic review was to characterize the existing literature on this topic and to evaluate the credibility of CBD as a candidate pharmacotherapy for alcohol use disorder (AUD). Using a comprehensive search strategy, 303 unique potential articles were identified [...]

Lire la suite